A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.

Yoshimi Tsuda; Christopher J. Parkins; Patrizia Caposio; F Feldmann; Sara Botto; Susan Ball; Ilhem Messaoudi; Luka Cicin-Sain; H Feldmann; Michael A. Jarvis

doi:10.1016/j.vaccine.2015.03.029

A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.

Yoshimi Tsuda
, Christopher J. Parkins
, Patrizia Caposio
, F Feldmann
, Sara Botto
, Susan Ball
, Ilhem Messaoudi
, Luka Cicin-Sain
, H Feldmann
, Michael A. Jarvis^*

^*Corresponding author for this work

School of Biomedical Sciences

Hokkaido University
National Institutes of Health
Oregon Health and Science University
University of California at Riverside
Helmholtz Centre for Infection Research

Research output: Contribution to journal › Article › peer-review

Abstract

Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

Original language	English
Pages (from-to)	2261-2266
Number of pages	0
Journal	Vaccine
Volume	33
Issue number	19
DOIs	https://doi.org/10.1016/j.vaccine.2015.03.029
Publication status	Published - 5 May 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cytomegalovirus
Disseminating
Durable
Ebola
Ebolavirus
Great apes
Mouse
Protection
Vaccine
Animals
Body Weight
Disease Models
Animal
Female
Genetic Vectors
Hemorrhagic Fever
Mice
Inbred C57BL
Survival Analysis
Vaccination
Viral Vaccines

Access to Document

10.1016/j.vaccine.2015.03.029

Cite this

@article{02d407e6ca4b4c7f88a9e345b50fe3b9,

title = "A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.",

abstract = "Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.",

keywords = "Cytomegalovirus, Disseminating, Durable, Ebola, Ebolavirus, Great apes, Mouse, Protection, Vaccine, Animals, Body Weight, Disease Models, Animal, Female, Genetic Vectors, Hemorrhagic Fever, Mice, Inbred C57BL, Survival Analysis, Vaccination, Viral Vaccines",

author = "Yoshimi Tsuda and Parkins, \{Christopher J.\} and Patrizia Caposio and F Feldmann and Sara Botto and Susan Ball and Ilhem Messaoudi and Luka Cicin-Sain and H Feldmann and Jarvis, \{Michael A.\}",

year = "2015",

month = may,

day = "5",

doi = "10.1016/j.vaccine.2015.03.029",

language = "English",

volume = "33",

pages = "2261--2266",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "19",

}

TY - JOUR

T1 - A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.

AU - Tsuda, Yoshimi

AU - Parkins, Christopher J.

AU - Caposio, Patrizia

AU - Feldmann, F

AU - Botto, Sara

AU - Ball, Susan

AU - Messaoudi, Ilhem

AU - Cicin-Sain, Luka

AU - Feldmann, H

AU - Jarvis, Michael A.

PY - 2015/5/5

Y1 - 2015/5/5

N2 - Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

AB - Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

KW - Cytomegalovirus

KW - Disseminating

KW - Durable

KW - Ebola

KW - Ebolavirus

KW - Great apes

KW - Mouse

KW - Protection

KW - Vaccine

KW - Animals

KW - Body Weight

KW - Disease Models

KW - Animal

KW - Female

KW - Genetic Vectors

KW - Hemorrhagic Fever

KW - Mice

KW - Inbred C57BL

KW - Survival Analysis

KW - Vaccination

KW - Viral Vaccines

U2 - 10.1016/j.vaccine.2015.03.029

DO - 10.1016/j.vaccine.2015.03.029

M3 - Article

SN - 0264-410X

VL - 33

SP - 2261

EP - 2266

JO - Vaccine

JF - Vaccine

IS - 19

ER -

A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this